Lily Center for Biotechnology in San Diego, California, on March 1, 2023.
Mike Blake Reuters
Eli Lily On Thursday, I reported mixed results for the fourth quarter, as sales of weight loss and diabetes increased, but they witnessed low prices.
The numbers were consistent with the initial results that Elie Lily participated in January, which was disappointed. Elie Lily was It reduced its revenue directions for 2024He also said that the demand for weight loss and diabetes will not fulfill its noble expectations.
The company's quarterly profits topped the Wall Street estimates, but sales were short.
The giant pharmaceutical company has also issued financial profit directions 2025 from 22.05 dollars to $ 23.55 per share, which is in line with what analysts expect. Eli Lily launched her financial sales directives 2025 from $ 58 billion to $ 61 billion.
Here is what Elie Lily told for the fourth quarter compared to what Wall Street expected, based on a survey of analysts by LSEG:
- Arrow's profits: 5.32 average $ 4.95 expected
- profit: 13.53 billion dollars compared to 13.57 billion dollars expected
The company recorded the fourth -quarter revenues of $ 13.53 billion, an increase of 45 % over the same period.
The pharmaceutical giant of the net income of $ 4.41 billion, or $ 4.88 per share, for the fourth quarter. This compares with a profit of $ 2.19 billion, or $ 2.42 per share, a year ago.
With the exception of the one -time items related to the value of unfinished assets and other assessments, El Lilly has published $ 5.32 per share per share for the fourth quarter of 2024.
This story is developing. Please check again for updates.
